Biodesix (NASDAQ:BDSX – Get Free Report) and Personalis (NASDAQ:PSNL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Institutional and Insider Ownership 21.0% of Biodesix shares are […]
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 181,100 shares, a growth of 12.1% from the February 29th total of 161,500 shares. Based on an average daily trading volume, of 115,700 shares, […]
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 196,700 shares, a growth of 32.9% from the January 15th total of 148,000 shares. Approximately 0.8% of the shares of the stock are sold short. Based on […]
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) CFO Robin Harper Cowie sold 10,156 shares of Biodesix stock in a transaction on Friday, February 9th. The shares were sold at an average price of $1.92, for a total value of $19,499.52. Following the completion of the sale, the chief financial officer now directly owns 178,109 shares […]
Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) CEO Scott Hutton sold 29,708 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $1.66, for a total transaction of $49,315.28. Following the transaction, the chief executive officer now directly owns 465,011 shares in the company, […]